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A B S T R A C T
Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for patients with a hematologic
malignancy due to alloreactive T cell responses recognizing minor histocompatibility antigens (MiHA). Yet
tumor immune escape mechanisms can cause failure of T cell immunity, leading to relapse. Tumor cells display
low expression of costimulatory molecules and can up-regulate coinhibitory molecules that inhibit T cell func-
tionality on ligation with their counter-receptors on the tumor-reactive T cells. The aim of this explorative
study was to evaluate immune checkpoint expression proﬁles on T cell subsets and on cytomegalovirus (CMV)-
and/or MiHA-reactive CD8+ T cells of allo-SCT recipients using a 13-color ﬂow cytometry panel, and to cor-
relate these expression patterns to clinical outcomes. MiHA-reactive CD8+ T cells exhibited an early differentiated
CD27++/CD28++ phenotype with low KLRG-1 and CD57 expression. These T cells also displayed increased ex-
pression of PD-1, TIM-3, and TIGIT compared with total effector memory T cells and CMV-speciﬁc CD8+ T cells
in healthy donors and allo-SCT recipients. Remarkably, high coexpression of PD-1, TIGIT, and KLRG-1 on MiHA-
reactive CD8+ T cells was associated with relapse after allo-SCT. Taken together, these ﬁndings indicate that
MiHA-speciﬁc CD8+ T cells of relapsed patients have a distinctive coinhibitory expression signature com-
pared with patients who stay in remission. This phenotype may serve as a potential monitoring tool in patients.
Moreover, these ﬁndings suggest that PD-1 and TIGIT play important roles in regulating T cell-mediated tumor
control, providing a rationale for immunotherapy with blocking antibodies to treat relapse after allo-SCT.
© 2017 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights
reserved.
INTRODUCTION
Immunotherapy is a potent treatment modality in hema-
tologicmalignancies. Awell-established example in this regard
is allogeneic stem cell transplantation (allo-SCT) [1,2], in which
a patient receives a donor hematopoietic stem cell graft to
replace host hematopoiesis and to invoke a graft-versus-
tumor (GVT) immune response toward residual malignant
cells. One important aspect in establishing successful GVT
immunity is the induction of donor CD8+ T cell responses tar-
geting recipient-speciﬁc minor histocompatibility antigens
(MiHAs) and tumor-associated antigens expressed by resid-
ual tumor cells. Upon activation, these T cells acquire effector
functions, and thereby the capacity to eradicate the malig-
nant cells [3,4].
Although allo-SCT can be curative due to establishment
of long-lived tumor-reactive T cell memory, relapse remains
the leading cause of treatment failure [5,6]. Tumor cells evade
T cell immunity by exploiting different mechanisms. Low ex-
pression of costimulatory molecules in combination with
increased expression of coinhibitory molecules by the tumor
cells is associated with poor prognosis [7]. Tumor-reactive T
cells can up-regulate coinhibitory receptors, including CTLA-
4, PD-1, and TIM-3, and subsequent inhibitory signaling
dampens T cell functionality [8-11]. We and others have
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previously demonstrated the inhibitory role of PD-1 and BTLA
on tumor-reactive T cell functionality in transplant recipi-
ents [12-14]. In recent years, antagonistic antibodies against
PD-1 and CTLA-4 have been investigated for treatment of mul-
tiple cancers, with impressive improvements in disease
outcomes [15-17]. However, not all patients respond, and
others acquire resistance to these checkpoint blockers. Re-
cently, a plethora of new coinhibitory molecules have been
implicated in tumor immune escape [8,18-22]. It has been
demonstrated that signaling through multiple coinhibitory
molecules on the same T cell can aggravate T cell dysfunc-
tion [8,23]. In this context, it has been shown that
simultaneous blockade of 2 or even 3 coinhibitory mol-
ecules, such as PD-1 and CTLA-4, leads to synergistic
improvement of antitumor T cell responses [20,24]. This
prompted us to investigate the expression proﬁles of a com-
prehensive panel of cosignaling receptors on MiHA-speciﬁc
CD8+ T cells of patients after allo-SCT and to analyze these
in relation to clinical outcome.
Here we analyzed the expression of 15 cosignaling mol-
ecules on T cell subsets of allo-SCT recipients (n = 30) and
healthy donors (n = 10) by 13-color ﬂow cytometry. Using te-
tramer technology, we identiﬁed (low-frequency) circulating
antigen-speciﬁc CD8+ T cells (cytomegalovirus [CMV], MiHA).
We observed distinct coexpression proﬁles of cosignalingmol-
ecules during T cell differentiation. Importantly, MiHA-
speciﬁc CD8+ T cells retained an early differentiated phenotype
with high expression of the costimulatory molecules CD27
and CD28, whereas CD57 expression was relatively low. In
addition, these T cells showed increased levels of PD-1, TIM-
3, and TIGIT. Of note, high coexpression of PD-1, TIGIT, and
KLRG-1 on MiHA-speciﬁc CD8+ T cells was associated with
relapse after allo-SCT. Taken together, the data from our ex-
plorative study suggest that multiple cosignaling molecules
may act together in regulating T cell-mediated tumor control.
Treatment with antibodies targetingmultiple cosignalingmol-
ecules would be an attractive adjuvant treatment strategy to
boost the potency of these highly activated, potentially dys-
functional, tumor-reactive T cells for treatment of relapse after
allo-SCT.
MATERIALS AND METHODS
Patient and Donor Material
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Hypaque (GE Life Sciences Healthcare, Chicago, IL) density centrifugation
of healthy donor buffy coats (Sanquin, Nijmegen, The Netherlands) or pe-
ripheral blood of allo-SCT recipients. Healthy donors were selected for
HLA-B7 positivity and presence of CMV-speciﬁc CD8+ T cells. Allo-SCT
recipient-donor pairs were screened for MiHA disparity using allele-
speciﬁc PCR [25]. Patients were selected based on detectable MiHA- or CMV-
speciﬁc CD8+ T cell responses following allo-SCT [4]. Patients were treated
as described previously [4]; characteristics are summarized in Table 1 and
Tables S1 and S2. Patient and donor material and data were obtained in ac-
cordance with the Declaration of Helsinki and institutional guidelines and
regulations (CMO 2013/064).
Flow Cytometry
Expression of coinhibitory and costimulatory molecules on PBMCs of
healthy donors and allo-SCT recipients was analyzed by 13-color ﬂow
cytometry. Cryopreserved cells were incubated for 15 minutes at room tem-
perature in PBS plus .5% BSA supplemented with 1 mg/mL total hIgG
(Sanquin). Thereafter, cells were stained with 0.2 μg BV605- and BV711-
labeled tetramers speciﬁc for the corresponding CMV or MiHA epitopes
(Table 2) [4], and incubated for 30 minutes at room temperature. Then cells
were labeled with the following antibodies: CD3-BV510 (UCHT1), CD8-
PerCP (SK1), CD45RA-Alexa Fluor 700 (HI100), CCR7-PE-CF594 (150503), and
CD56-BUV737 (NCAM16,2; all from BD Biosciences, San Jose, CA). For de-
tecting costimulatory and coinhibitory molecules, the following antibodies
were used: CD27-FITC (M-T271), ICOS-PE (DX29), CD28-PE-Cy7 (CD28.2),
CD137-APC (4B4-1), CTLA-4-BV421 (BNI3), 2B4-PE (2-69), CD57-BV421
(NK-1), BTLA-PE (J168-540), and PD-1-BV421 (EH12.1), all from BD Biosci-
ences; CD200R-FITC (380525), TIGIT-APC (741182), LAG-3-APC (polyclonal
goat IgG), and IgG-APC, from R&D Systems (Minneapolis MN); OX-40-PE-
Cy7 (BER-ACT35), TIM-3-PE-Cy7 (F38-2E2), IgG1-FITC, -PE, -APC, and -BV421
(MOPC-21), IgG2a-FITC, -PE, and -BV421 (MOPC-173), IgG2b-FITC, and -APC
(MPC-11), from Biolegend (San Diego, CA); KLRG-1-FITC (REA261), from
Miltenyi Biotec (Bergisch Gladbach, Germany), and IgG1-PE-Cy7 (679.1Mc7),
from Beckman Coulter (Fullerton, CA). Cells were incubated for 30 minutes
at 4°C and then washed with PBS. For live/dead discrimination, cells were
then incubated for 30 minutes at 4°C with 1:1000 diluted Fixable Blue Dead
Cell kit (Thermo Fisher Scientiﬁc, Waltham, MA). The panel design and laser
alignment are summarized in Table S3. Cells were analyzed on a 5-laser
FACSAria II cell sorter (BD Biosciences).
Data and Statistical Analysis
Flow cytometry data were analyzed using Kaluza version 1.5a (Beckman
Coulter) or FlowJo version 10.2 (FlowJo, Ashland, OR). The gating strategy
is depicted in detail in Figure S1. First, singlets and live cells were gated, then
autoﬂuorescence negative cells (using an unstained empty ﬂow channel) were
selected, and subsequently lymphocytes were gated using forward and side
scatter. CD4+ T cells were deﬁned as CD56-CD3+CD8-; CD8+ T cells, as
CD56-CD3+CD8+. Within the CD8+ T cell population, CMV- or MiHA-
speciﬁc T cells were gated as positive for both tetramer-BV605 and tetramer-
BV711. Furthermore, memory cell subsets were gated and deﬁned as follows:
CCR7+CD45RA+ naïve(-like) T cells (Tn), CCR7+CD45RA− central memory T
cells (Tcm), and CCR7− effector/effector memory T cells (Tem). Isotype-
matched controls were used to evaluate the positivity for the cosignaling
molecules; that is, each isotype gate was set at ≤1% positive. Tetramer-
positive CD8+ T cell populations were also analyzed using the bh-SNE
algorithm in CYT version 2.0 from the Dana Pe’er Lab of Computational
Systems Biology (New York, NY) andMATLAB (MathWorks, Natick, MA) [26].
In brief, the algorithm converts multidimensional data into bidimensional
maps by ﬁrst calculating a pairwise distance matrix for the high-dimensional
space and then transforming it into a similarity matrix using a varying Gauss-
ian kernel. A random bidimensional map is rendered, and pairwise similarities
are calculated for the low-dimensional space created. The map is then op-
timized in iteration steps using the calculated similarity between any given
2 cells to optimally redistribute them on the map. Data quantiﬁcations were
made in Prism version 5.03 (GraphPad Software, La Jolla, CA), SPICE version
5.3 (National Institute of Allergy and Infectious Diseases, Rockville, MD) and
CIMminer (National Institutes of Health, Bethesda, MD) [27]. For a statis-
tical comparison of SPICE pie charts, the built-in test in SPICE software was
used, applying 1,000,000 permutations; as described by Roederer et al. [28]
and Legat et al. [29]. For heatmap clustering analyses in CIMminer soft-
ware with average linkage and the Pearson coeﬃcient was used to determine
the correlation between subset populations and expression of the differ-
ent cosignaling molecules. Other P values were obtained using a 2-tailed
t test or 1-way analysis of variance followed by a Bonferroni post hoc test
as indicated, with *P < .05, **P < .01, and ***P < .001.
RESULTS
Distinct Coinhibitory Molecule Expression Proﬁles During
T Cell Differentiation
To evaluate differences in T cell subset composition and
expression proﬁles of cosignaling molecules, CD4+ and CD8+
T cells of healthy donors and allo-SCT recipients (at a median
of 6 months after allo-SCT; range, 1-40 months) were ana-
lyzed by ﬂow cytometry. Figure 1A shows representative ﬂow
cytometry plots of the CD4+ and CD8+ T cell subsets in a
healthy donor and an allo-SCT recipient. The majority of both
CD4+ and CD8+ T cells of allo-SCT recipients had a Tem phe-
notype (CD4+, 65.3 ± 3.2%; CD8+, 86.4 ± 1.6%), whereas these
populations were substantially smaller in healthy donors
(CD4+, 29.8 ± 3.4%; CD8+, 68.4 ± 4.0%; Figure 1B and Table S2).
Of note, the CD45RA+CCR7+ T cell population of allo-SCT re-
cipients contains both genuine naïve T cells and CD95+ “naïve-
like” or stem cell memory T cells, as we described previously
[30]. Subsequently, we determined cosignaling molecule ex-
pression levels on CD4+ and CD8+ T cell memory subsets of
healthy donors, and performed unsupervised clustering anal-
yses (Figure 1C). Interestingly, for the CD8+ T cells, perfect
clustering of the different differentiation stages was ob-
served based on distinct expression proﬁles of cosignaling
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Table 1
Patient Characteristics
Patient Disease CMV Reactivation,
mo after Allo-SCT
Antigen-Speciﬁc CD8+
T Cell Response
(HLA Restriction)
Sampling
Date, mo after
Allo-SCT
DLI before Sampling
Date, mo after
Allo-SCT
Disease Status at
Sampling Date
GVHD at Sampling
Date
ISD at Sampling
Date
Relapse, mo
after Allo-SCT
Alive at Last
FU, mo after
Allo-SCT
1 MM No HA-1 (A2) 6 Yes, 6 (prophylactic) CR No No No Yes, 86
2 NHL No SP110 (A3) 3 Yes, 2 (boost) CR Yes, aGVHD grade III MMF, prednisone,
etanercept, and
inolimomab
No
3 CML No HA-1 (A2) 6 Yes, 4 (prophylactic) CR Yes, aGVHD grade III No No No, 15 (NRM)
4 MDS No HY (B7) 8 No CR Yes, cGVHD, extensive No No Yes, 43
5 MDS No HA-1 (A2) 5 No CR No Tacrolimus No Yes, 24
6 MDS Yes, 8 HA-1 (A2) 11 Yes, 6 (prophylactic) CR Yes, cGVHD, extensive CSA and prednisone No No, 49 (NRM)
7 AML No ARHGDIB (B7) 7 Yes, 6 (prophylactic) CR Yes, aGVHD grade I CSA and prednisone No Yes, 151
8 AML N.A. HY (A2) 12 No CR No (resolved) CSA No Yes, 199
9 AML No HA-1 (A2) 1 No CR No CSA No Yes, 39
10 AML Yes, 4 ARHGDIB (B7) 6 No CR Yes, cGVHD, extensive CSA and prednisone No Yes, 39
11 AML N.A. HA-8 (A2) 6 No CR Yes, cGVHD, mild CSA No Yes, 255
12 AML N.A. ARHGDIB (B7) 14 Yes, 8 (prophylactic) CR No No No Yes, 145
13 MM No PANE (A3) 6 No CR Yes, cGVHD, mild No Yes, 9 No,10 (RRM)
14 NHL No HY (A2) 4 Yes, 4 (therapeutic) Relapse No CSA Yes, 3 No, 19 (RRM)
15 NHL No ARHGDIB (B7) 11 No CR No No Yes, 21 Yes, 250
16 CML No LRH-1 (B7) 14 Yes, 10 + 12 (therapeutic) Relapse No No Yes, 9 No, 75 (RRM)
17 AML No LRH-1 (B7) 40 Yes, 5 (prophylactic) Relapse No No Yes, 38 and 75 No, 94 (RRM)
18 AML No HY (A2) 3 No CR Yes, aGVHD, grade III MMF Yes, 10 No, 10 (RRM)
19 AML No HY (A2) 5 No Relapse No No Yes, 4 No, 5 (RRM)
20 AML No ARHGDIB (B7) 3 No MRD Yes, aGVHD, grade II No No Yes, 32
FU indicates follow-up; NHL, non-Hodgkin lymphoma; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; MM, multiple myeloma; MDS, myelodysplastic syndrome; Cy, cyclophosphamide; MRD, minimal
residual disease; DLI, donor lymphocyte infusion; CR, complete remission; NA, not available; cGVHD, chronic graft-versus-host-disease; aGVHD, acute graft-versus-host-disease; ISD, immunosuppressive drugs; CSA, cyclosporin
A; MMF, mycophenolic acid; RRM, relapse-related mortality; NRM, nonrelapse mortality.
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molecules. In case of the CD4+ T cells, the clustering was
partial. As expected, CD27, CD28, and BTLA were highly
expressed by naïve CD4+ and CD8+ T cells, and expression grad-
ually decreased on T cell differentiation. In contrast, expression
of KLRG-1, CD57, PD-1, and TIGIT was gained during T cell dif-
ferentiation, with highest expression levels on Tem cells [29].
Of note, in allo-SCT recipients, clustering of T cell differen-
tiation stages was also observed based on cosignaling
expression proﬁles, despite differences in expression levels
from healthy controls (data not shown).
We next investigated whether cosignaling molecules were
differentially expressed by the different effector/memory T
cell subsets of healthy donors compared with allo-SCT pa-
tients. The results are displayed for CD4+ T cells (Figure 2) and
for CD8+ T cells (Figure 3). A slight decrease in CD28 expres-
sion on CD8+ T cells of allo-SCT recipients was observed
compared with healthy donors. Furthermore, we detected in-
creased OX-40 expression on the CD4+ Tcm and Tem cells of
allo-SCT recipients, and elevated ICOS expression on the Tcm
cells. Interestingly, KLRG-1 was expressed by the “naive-
like” T cells, whereas PD-1 and CD57 expression was
signiﬁcantly higher on Tcm and Tem of both the CD4+ and
CD8+ T cell populations in allo-SCT recipients. Collectively,
these data indicate that the CD4+ and CD8+ T cell popula-
tions of allo-SCT recipients have distinct cosignaling molecule
proﬁles that change during T cell differentiation, similar to
those of healthy donors.
MiHA-Speciﬁc CD8+ T Cells Show an Early Differentiation
Phenotype Accompanied with High Expression of
Coinhibitory Molecules
We next examined the cosignaling molecule expression
proﬁles on antigen-speciﬁc CD8+ T cells. We comparedMiHA-
speciﬁc CD8+ T cells with CMV-speciﬁc CD8+ T cells from
healthy donors and allo-SCT recipients using a ﬂow cytometry-
based dual-color tetramer staining approach [4]. Figure 4A
shows representative ﬂow cytometry plots of CMV- and
MiHA-speciﬁc CD8+ T cells and their respective effector/
memory subset composition. Almost all CMV-speciﬁc CD8+
T cells from both healthy donors (84.6 ± 7.7%) and allo-SCT
recipient (95.1 ± 1.3%) displayed a Tem phenotype, as did the
MiHA-speciﬁc CD8+ T cells (91.9 ± 1.6%; Figure 4B and Table
S1). Therefore, we compared the expression of cosignaling
molecules on CMV- and MiHA-speciﬁc CD8+ T cells with the
corresponding expression proﬁles of the total CD8+ Tem cell
population of allo-SCT recipients (data for healthy donors are
provided in Figure S2). The phenotype of MiHA-speciﬁc CD8+
T cells was found to differ signiﬁcantly from that of the total
CD8+ Tem population and CMV-speciﬁc CD8+ T cells based on
augmented expression of CD27, CD28, CD278 (ICOS), and
CD137 (4-1BB) (Figure 4C and D). In addition, we observed
lower expression levels of KLRG-1 and CD57 onMiHA-speciﬁc
CD8+ T cells, reﬂecting their early differentiation stage. Of note,
along with lower expression of terminal differentiation
markers and increased expression of the aforementioned
costimulatory molecules, signiﬁcantly elevated levels of PD-
1, TIM-3, and TIGIT were observed as well. Findings were
similar for percentage of positive cells and expression based
on mean ﬂuorescence intensity (data not shown). Taken to-
gether, these data indicate that MiHA-speciﬁc CD8+ T cells
display a recently activated and early differentiation pheno-
type with high expression of PD-1, TIGIT, and TIM-3, which
may be the result of activation-induced up-regulation [29],
but also could reﬂect T cell exhaustion.
MiHA-Speciﬁc CD8+ T Cells Exhibit Distinctive Clustering
Proﬁles with Increased Expression of Inhibitory and
Stimulatory Receptors
Coexpression proﬁles of cosignalingmolecules on antigen-
speciﬁc CD8+ T cells of healthy donors and allo-SCT recipients
were compared using different clustering analyses. First,
tetramer-positive T cell populations were analyzed using the
bh-SNE algorithm. Here analysis was performed separately
for each ﬂow cytometry panel, clustering individual CMV- or
MiHA-speciﬁc CD8+ T cells based on the ﬂuorescence inten-
sities of the 5 cosignaling molecules in each panel (Figure 5A
and Figure S3). Interestingly, MiHA-speciﬁc CD8+ T cells ex-
hibited a distinct clustering pattern compared with CMV-
reactive CD8+ T cells based on differential expression of CD27,
CD28, and CD137 (panel 1; Figure S3A); high TIGIT and lack
of CD57 (panel 2, Figure S3B); and high expression of PD-1,
TIM-3, and BTLA and lack of KLRG-1 (panel 3, Figure S3C).
Of note, the clustering patterns seen for the CMV-speciﬁc CD8+
T cells of healthy donors versus allo-SCT recipients were rel-
atively similar (Figure 5A). These data were conﬁrmed by
unsupervised cluster analysis, displayed in a heatmap, where
MiHA-speciﬁc CD8+ from allo-SCT recipients clustered to-
gether in a distinctive pattern compared with CMV-speciﬁc
CD8+ T cells (Figure 5B). These differences could be attrib-
uted predominately to increased expression of costimulatory
CD27 and CD28, collectively with elevated levels of
coinhibitory PD-1, TIGIT, TIM-3, and BTLA on the MiHA-
speciﬁc CD8+ T cells.
To look at these coexpression proﬁles from a different
angle, we performed additional SPICE analysis. This analy-
sis demonstrated that almost all of the MiHA-speciﬁc CD8+
T cells expressed CD27 and CD28 (Figure 5C). Furthermore,
this population contained a higher proportion of cells triple-
positive for CD27, CD28, and CD137 compared with CMV-
speciﬁc CD8+ T cells, regardless of healthy donor or allo-SCT
recipient origin. Furthermore, the MiHA-speciﬁc CD8+ T cell
population showed lower expression of the terminal differ-
entiation marker CD57 and contained a higher frequency of
TIGIT+CD57− cells. Finally, MiHA-speciﬁc CD8+ T cells showed
increased coexpression of PD-1, TIM-3, and BTLA, whereas
lower KLRG-1 levels were observed compared with CMV-
speciﬁc CD8+ T cells. Of note, in all 3 panels, MiHA-speciﬁc
CD8+ T cells coexpressed signiﬁcantly more cosignaling mol-
ecules than CMV-speciﬁc CD8+ T cells. This was especially
striking in panel 3, where the average proportion of cells
coexpressing ≥3 coinhibitory molecules was 57.2 ± 5.6% (SEM)
for the MiHA-speciﬁc CD8+ T cells, versus only 25.1 ± 5.7% and
30.0 ± 6.6%, respectively, in CMV-speciﬁc CD8+ T cells of
healthy donors and allo-SCT recipients. Taken together, these
ﬁndings indicate that MiHA-speciﬁc CD8+ T cells exhibit dis-
tinctive clustering proﬁles, with an increased proportion of
cells simultaneously expressing multiple coinhibitory
Table 2
CMV- or MiHA-Speciﬁc Peptide Sequences Used for Tetramer-based Anal-
ysis of Antigen-Speciﬁc T Cell Populations
Antigen HLA Restriction Sequence
CMV B7 RPHERNGFTVL
HA-1 A2 VLHDDLLEA
HA-8 A2 RTLDKVLEV
HY A2 FIDSYICQV
PANE A3 RVWDLPGVLK
SP110 A3 SLPRGTSTPK
ARHGDIB B7 LPRACWREA
HY B7 SPSVDKARAEL
LRH-1 B7 TPNQRQNVC
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molecules, including PD-1, TIM-3, and TIGIT, as well as CD27
and CD28.
High Expression of OX-40, PD-1, TIGIT, and KLRG-1 on
MiHA-Speciﬁc CD8+ T Cells Is Associated with Relapse in
Allo-SCT Recipients
Finally, we evaluated whether distinct T cell expression
signatures showed associations with clinical outcomes. To do
so, we compared the expression of cosignaling molecules
on MiHA-speciﬁc CD8+ T cells of patients remaining in
remission (n = 12; patients 1-12) with those of patients with
persistent or relapsed disease after allo-SCT (n = 8; patients
13-20). Themedian age at transplantationwas 43 years (range,
28-58 years) for the relapsed patients versus 50 years (range,
26-63 years) in the remission group. Analyzed samples were
obtained at a median of 11months (range, 3-40months) after
allo-SCT for relapsed patients versus 7 months (range, 1-14
months) for nonrelapsed patients. At the time of analysis, 8
of 12 patients in remission were still being treated with
immunosuppressive drugs, compared with 2 of 8 relapsed
Figure 1. Cosignaling molecules show distinct coexpression proﬁles during T cell differentiation. CD4+ and CD8+ T cell subsets of healthy donors (HD) and
allo-SCT recipients (allo-SCT patients) were examined for expression of coinhibitory and costimulatory molecules using ﬂow cytometry. T cell differentiation
stages were analyzed by gating on CD45RA and CCR7 expression. (A) Representative ﬂow cytometry plots of the CD8+ and CD4+ subset composition in 1 HD
and 1 allo-SCT pt (no. 3). (B) Combined data of CD4+ and CD8+ T cell subset composition for the HDs and allo-SCT recipients (HD: n = 10; allo-SCT pt: n = 30).
Naïve/naïve-like T cells (Tn), CD45RA+CCR7+ (black); central memory T cells (Tcm), CD45RA− CCR7+ (gray); effector memory T cells (Tem), CCR7− (white). Data
are shown as mean ± SEM for each subset as proportion of the CD4+ and CD8+ T cell populations. (C) Unsupervised clustering analysis with the Pearson co-
eﬃcient was performed on cosignaling molecule expression levels on CD4+ and CD8+ T cells of HDs (n = 10). Data are shown in a heat map with a color code
showing expression from 0% (blue) to 100% positivity (red) for the corresponding marker. Each row represents a different cosignaling molecule, and each column
represents a T cell subset from 1 particular donor. Below the heat map, the classical differentiation stages based on CD45RA and CCR7 expression are indi-
cated with a colored asterisk: green, Tn; orange, Tcm; red, Tem.
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Figure 2. OX-40, ICOS, CD57, PD-1, and TIGIT are expressed at higher levels by CD4+ memory T cells of allo-SCT recipients. Expression of cosignaling mol-
ecules in the context of CD4+ T cell differentiation was analyzed using ﬂow cytometry for healthy donors (HDs, white bars; n = 10) and allo-SCT recipients
(allo-SCT pts, gray bars; n = 30). Statistical analysis was performed using a 2-tailed t test. *P < .05; **P < .01; ***P < .001.
Figure 3. PD-1 and CD57 are highly expressed by CD8+ memory T cells of allo-SCT recipients. Expression of cosignaling molecules in the context of CD8+ T
cell differentiation was analyzed by ﬂow cytometry for healthy donors (HDs, white bars; n = 10) and allo-SCT recipients (allo-SCT pts, gray bars; n = 30). Sta-
tistical analysis was performed using a 2-tailed t test. *P < .05; **P < .01; ***P < .001.
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Figure 4. MiHA-speciﬁc CD8+ T cells exhibit an early differentiation phenotype accompanied with high expression of coinhibitory molecules. Antigen-
speciﬁc CD8+ T cells of healthy donors (HDs) and allo-SCT recipients (allo-SCT patients) were examined for expression of coinhibitory and costimulatory molecules
using dual-color tetramer-based ﬂow cytometry. (A) Representative plots of CMV- and MiHA-speciﬁc CD8+ T cells and their respective differentiation stage
are shown for 1 HD and 1 allo-SCT pt (no. 24) with a detectable CMV-speciﬁc CD8+ T cell response, and 1 allo-SCT pt (no. 15) with a detectable MiHA-speciﬁc
CD8+ T cell response. The number in the plots indicates the percentage of MiHA-speciﬁc CD8+ T cells positive for both tetramers. (B) Combined data of the
subset composition within the antigen-speciﬁc CD8+ T cell population are shown (HD, n = 10; allo-SCT pt CMV, n = 10; allo-SCT pt MiHA, n = 20). Naïve-like T
cells (Tn), CD45RA+CCR7+ (black); central memory T cells (Tcm), CD45RA− CCR7+ (gray); effector memory T cells (Tem), CCR7− (white). Data are expressed as
mean ± SEM for each subset as proportion of the antigen-speciﬁc CD8+ T cell populations. (C) Surface expression of the different cosignaling molecules is shown
for the MiHA-speciﬁc CD8+ T cell population (black) and CD8+ T cell subsets of 1 allo-SCT pt (no. 7) (Tn, green; Tcm, orange; Tem, red), compared with the
corresponding isotype control staining (gray). Dotted lines represent gates set at <1% positive for the isotype control, and the numbers in the plots represent
the percentage of cells positive for the respective receptor. (D) Combined data showing the percentage of cells positive for each cosignaling molecule within
the total CD8+ Tem versus CMV- and MiHA-speciﬁc CD8+ T cell populations of allo-SCT pt (allo-SCT pt Tem, n = 30; allo-SCT pt CMV, n = 10; allo-SCT pt MiHA,
n = 20). Statistical analysis was performed using 1-way analysis of variance followed by a Bonferroni post hoc test.*P < .05; **P < .01; ***P < .001.
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patients. This corresponds with the higher rate of graft-
versus-host disease (GVHD) in the remission group (7 of 12)
versus the relapse group (3 of 8). There were no differences
in donor lymphocyte infusion administration between the
patient groups. Of note, none of the patients with a MiHA-
speciﬁc CD8+ T cell response had detectable CMV disease at
the sampling date.
We found signiﬁcantly higher expression of OX-40, KLRG-
1, PD-1, and TIGIT on MiHA-speciﬁc CD8+ T cells of allo-SCT
recipients who relapsed (Figure 6A). The other cosignaling
moleculeswere not differentially expressed and did not exhibit
any differences in coexpression patterns (Figure 6A and Figure
S4). Observations were similar for percentage positive cells
and expression based on mean ﬂuorescence intensity (data
not shown). To further demonstrate that coexpression of OX-
40, KLRG-1, PD-1, and TIGIT deﬁned a distinct T cell signature
in patients who relapsed after allo-SCT, we established a new
panel dedicated to these 4 receptors and remeasured MiHA-
speciﬁc CD8+ T cells of 9 patients with mostly myelogenous
malignancies (remission patients: 5, 8, 9, 11 and 12; relapse
patients: 15, 17, 19, and 20) (Figure 6B). Interestingly, the
relapsed patients had a small subset of quadruple-positive
Figure 5. MiHA-speciﬁc CD8+ T cells have a distinct coexpression proﬁle with high expression of inhibitory and stimulatory receptors. Antigen-speciﬁc CD8+
T cells of healthy donors (HDs) and allo-SCT recipients (allo-SCT pts) were examined for expression of coinhibitory and costimulatory molecules by ﬂow cytometry
using 3 different panels. CMV- and MiHA-speciﬁc CD8+ T cells were gated based on dual-color tetramer staining. (A) bh-SNE clustering analysis was per-
formed for each ﬂow cytometry panel, containing 5 antibodies against different cosignaling molecules. Composite overlays (left) and individual maps (right)
visualize the clustering signatures of HD CMV (green), allo-SCT pt CMV (yellow), and allo-SCT pt MiHA (red). (B) Unsupervised average linkage analysis was
performed with the Pearson coeﬃcient for each antigen-speciﬁc CD8+ T cell population, and is displayed in a heat map. The color scale indicates expression
from 0% (blue) to 100% positivity (red) for the corresponding marker. Each row represents a different cosignaling molecule, and each column represents a
different individual. Below the heat map, the donor population and corresponding antigen speciﬁcities are indicated with colored asterisks: green, HD CMV;
orange, allo-SCT Pt CMV; red, allo-SCT MiHA Pt. (C) Coexpression patterns were determined with SPICE software. The pies depict the average proportion of
cells expressing 0 to 5 of the cosignaling molecules, and the arcs indicate which markers are expressed by the corresponding pies. Statistical differences were
analyzed using the built-in statistical tool. *P < .05; **P < .01; ***P < .001. HD CMV, n = 10; allo-SCT Pt CMV, n = 10; allo-SCT Pt MiHA, n = 20.
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Figure 6. High expression of PD-1, TIGIT, OX-40, and KLRG-1 on MiHA-speciﬁc CD8+ T cells is associated with relapse in allo-SCT recipients. Expression levels
of cosignaling molecules on MiHA-speciﬁc CD8+ T cells of allo-SCT recipients (allo-SCT pts) were evaluated using ﬂow cytometry and analyzed in the context
of relapse post-transplantation. (A) For each receptor, the percentage of positive cells was determined within the MiHA-speciﬁc CD8+ T cell populations of
nonrelapsed patients (n = 12; open circles) and relapsed patients (n = 8; black solid squares). Lines indicate the mean. Statistical analysis was performed using
a 2-tailed t test. *P < .05; ***P < .001. (B) Coexpression proﬁles of a dedicated panel speciﬁc for the 4 receptors that were signiﬁcantly differentially expressed
in nonrelapsed versus relapsed allo-SCT recipients were examined with ﬂow cytometry and analyzed using SPICE software. The pie charts depict the average
proportion of cells expressing 0 to 4 of the cosignaling molecules, and the arcs indicate whether KLRG-1 (red), OX-40 (green), TIGIT (light blue), and/or PD-1
(dark blue) is expressed by the corresponding pies. Statistical differences were analyzed using the built-in statistical tool.
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MiHA-speciﬁc CD8+ T cells that was not found in the remis-
sion patient group. Furthermore, in the relapsed patients, a
larger proportion of theMiHA-speciﬁc CD8+ T cells was triple-
positive. The expression of OX-40 and TIGIT seemedmutually
exclusive. Importantly, this expression signature was inde-
pendent of treatment with immunosuppressive drugs and
GVHD occurrence (data not shown). To conclude, our explor-
ative studies show that MiHA-speciﬁc T cells of relapsed
patients exhibit a distinct phenotype characterized by en-
hanced coexpression of PD-1, TIGIT, and KLRG-1. This
expression signature may be the result of T cell activation or
may reﬂect T cell dysfunction due to continuous antigen en-
counter. Treatment with novel combinations of antagonistic
and agonistic antibodies would be an attractive strategy
to boost the potency of these T cells to treat relapse after
allo-SCT.
DISCUSSION
The involvement of cosignaling molecules in tumor
immune escapemechanisms has become increasingly evident
in recent years. The impressive results achieved in clinical
trials blocking the PD-1/PD-L1 axis in solid and hemato-
logicmalignancies [15] illustrate the potent effects of releasing
the coinhibitory “breaks” on reinvigoration of antitumor im-
munity. Dysfunctional T cells can simultaneously express
multiple coinhibitory receptors, and subsequent signaling can
contribute to their dysfunctional state. Interestingly, com-
bined blockade of CTLA-4 and PD-1 resulted in additive or
even synergistic clinical eﬃcacy in cancer patients [24,31].
In addition to CTLA-4 and PD-1, novel cosignaling mol-
ecules are now being investigated, including BTLA, LAG-3, TIM-
3, and TIGIT [8-11,32]. We previously reported the
involvement of PD-1 and BTLA signaling in suppressingMiHA-
speciﬁc CD8+ T cell functionality, which could be alleviated
by antibody-mediated blockade in vitro [13]. However, not
all patients respond to single antibody therapy, which may
reﬂect differences in the dominance of immunosuppressive
mechanisms used by the tumor [13,15-17]. This empha-
sizes the need for new immunotherapeutic strategies targeting
novel combinations of coinhibitory molecules, and poten-
tially also costimulatory receptors, to boost tumor-reactive
T cell responses. The aim of this study was to identify
(co)expression proﬁles of a comprehensive set of cosignaling
molecules on MiHA-speciﬁc CD8+ T cells in relation to clin-
ical outcome after allo-SCT. Major challenges of multicolor
ﬂow cytometry include the complex data analyses and limi-
tations of 2D data visualization. Here we analyzed our data
extensively through unsupervised clustering, bh-SNE, and
SPICE analyses to elucidate potential expression signatures
associated with clinical outcomes.
We used a well-established T cell effector/memory subset
deﬁnition based on CD45RA and CCR7 expression [33] to eval-
uate the expression patterns of 15 cosignaling molecules
during T cell differentiation using unsupervised clustering
analysis. Interestingly, Tn, Tcm, and Tem clustered perfectly
together for the CD8+ T cells based on deﬁned cosignalingmol-
ecule expression patterns. Partial clustering was observed for
the CD4+ T cell subsets. These data illustrate the impor-
tance of evaluating cosignaling molecule expression proﬁles
in the context of T cell differentiation. In accordance with this,
others also have reported that changes in the expression of
CD27, CD28, BTLA, KLRG-1 and CD57 are correlated with T
cell differentiation stages [29,34]. Here we analyzed CD4+ and
CD8+ T cell subsets of healthy donors versus allo-SCT
recipients. We observed that allo-SCT recipients had signiﬁ-
cantly higher expression of PD-1 and CD57 on CD4+ and CD8+
Tcm and Tem populations, and increased levels of OX-40 in
Tcm and Tem CD4+ T cells. These data support that T cells of
allo-SCT recipients exhibit a highly activated/terminally dif-
ferentiated phenotype [35]. These observations likely can be
attributed to inﬂammation caused by the conditioning
regimen [36], viral reactivation, development of antiviral and
alloreactive immune responses, and occurrence of GVHD
[37,38].
We next studied the (co)expression patterns of cosignaling
molecules onMiHA-speciﬁc CD8+ T cells, because these target
highly immunogenic antigens expressed by hematologic
tumor cells. CMV-reactive CD8+ T cells served as controls for
MiHA-speciﬁc CD8+ T cells. We identiﬁed increased expres-
sion levels of multiple coinhibitory molecules, including PD-
1, TIM-3, and TIGIT, on MiHA-speciﬁc CD8+ T cells, whereas
these T cells retained an early differentiation phenotype with
lower CD57 and KLRG1 and high CD27 and CD28 expres-
sion. The distinctive phenotype of the MiHA-speciﬁc CD8+ T
cells compared with CMV-speciﬁc CD8+ T cells was also con-
ﬁrmed with bh-SNE analysis and unsupervised clustering
analysis and could be attributed to increased expression levels
of PD-1, TIGIT, TIM-3, BTLA, CD27, and CD28. Notably, a larger
proportion of MiHA-speciﬁc CD8+ T cells simultaneously ex-
pressed multiple cosignaling molecules at their cell surface
compared with CMV-speciﬁc CD8+ T cells. High expression
of coinhibitory molecules, such as PD-1, TIM-3, and TIGIT, by
tumor-reactive T cells can reﬂect T cell activation, but also
may be a hallmark of functional impairment [8,9,18-22]. Al-
though individual expression of coinhibitory receptors is not
selective or indicative of exhaustion, simultaneous expres-
sion of multiple coinhibitory receptors is a key feature of T
cell dysfunction in cancer and chronic viral infections
[10,11,35]. These coexpression patterns are mechanistically
relevant, because these receptors can act together in impair-
ing T cell function. Simultaneous blockade of multiple
coinhibitory molecules can result in synergistic reversal of
T cell dysfunction, as has been demonstrated for PD-1 and
TIM-3 and for PD-1 and TIGIT [21,32,35].
Most importantly, we analyzed the phenotype of MiHA-
speciﬁc CD8+ T cells in relation to clinical outcome. MiHA-
speciﬁc CD8+ T cells of patients who relapsed showed
increased expression of PD-1, TIGIT, OX-40, and KLRG-1. This
is in accordance with the results published by Schnorfeil et al.
[39], who reported increased PD-1 expression on total CD8+
T cells to correlate with relapse. Similarly, Kong et al. [40] re-
ported the association of high PD-1 and TIM-3 coexpression
with leukemia relapse in patients with acute myelogenous
leukemia after allo-SCT. In addition, TIGIT was found to be
associated with CD8+ T cell exhaustion and poor clinical
outcome in acute myelogenous leukemia [14]. Further-
more, up-regulation of the costimulatory molecules OX-40
and 4-1BB was observed on dysfunctional CD8+ TIL in human
and murine melanoma [41,42]. Interestingly, in our analy-
ses, approximately 10% of the T cells simultaneously expressed
the 4 markers PD-1, TIGIT, OX-40, and KLRG-1, although TIGIT
and OX-40 seemed mutually exclusive on the other MiHA-
speciﬁc CD8+ T cells. On average, more than one-half of the
cells were positive for ≥3 of these markers in the relapsed
group. In contrast, only ~25% of theMiHA-speciﬁc CD8+ T cells
were triple-positive in patients who remained in remission.
Notably, this expression signature was independent of the
type of MiHA-speciﬁc CD8+ T cell response, CMV reactiva-
tion, treatment with immunosuppressive drugs, and GVHD
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occurrence. In the future, this signature may potentially be
used for monitoring after allo-SCT.
This study has some limitations that should be addressed.
Owing to limited availability of material, it was not possi-
ble to include more patients, select patients with a similar
malignancy and/or MiHA-speciﬁc T cell response, use samples
obtained at ﬁxed time points after allo-SCT, or study kinet-
ics of checkpoint proﬁles. Malignant cell intrinsic factorsmight
have differentially altered coexpression proﬁles of check-
point molecules on MiHA-speciﬁc CD8+ T cells. In addition,
the local tumor microenvironment may play a signiﬁcant role
in modulating T cell phenotype and functionality. There-
fore, in the analyses with the dedicated PD-1, TIGIT, OX-40,
and KLRG-1 panel, mostly MiHA-speciﬁc CD8+ T cells of pa-
tients with myeloid malignancies were examined (7 with
acute myelogenous leukemia, 1 with myelodysplastic syn-
drome, 1 with non-Hodgkin lymphoma). Future studies in
larger, more homogenous cohorts are warranted to validate
our ﬁndings and further elucidate the functional conse-
quences and clinical importance of the expression signatures
described in this explorative study.
Combined targeting of PD-1, TIGIT, OX-40, and KLRG-1may
allow tailored tuning of the type andmagnitude of the tumor-
reactive T cell responses. In previous ex vivo studies, we
demonstrated that PD-1- and BTLA-expressingMiHA-reactive
T cells respond to PD-1 and/or BTLA blockade, with the most
pronounced effects observed for patients who relapsed after
allo-SCT [12]. In addition to enhanced signaling via
coinhibitory molecules, it has become clear that desensiti-
zation of costimulatory molecule signaling through the loss
of adaptor molecules is another mechanism that can con-
tribute to T cell dysfunction [43]. This indicates that both
costimulatory and coinhibitory receptors are appealing targets
for parallel agonistic and antagonistic antibody treatment. In
solid cancers, monotherapy with antagonistic or agonistic an-
tibodies targeting PD-1, TIGIT, or OX-40 has shown promising
results [20]. Importantly, CTLA-4 and PD-1/PD-L1 blockade
are now established treatment options for multiple solid
cancers, and combination therapywith anti-TIGIT and/or anti-
OX-40 is emerging [20,21,35,44]. Chauvin et al. [35] reported
that dual blockade of TIGIT and PD-1 potently augmented an-
titumor CD8+ T cell responses, as indicated by increased
proliferation, cytokine production, and degranulation in vitro.
Furthermore, OX-40 agonistic antibody treatment has been
reported to promote proliferation and survival of activated
CD8+ T cells [45,46]. The crux of allo-SCT is the separation
of GVT and GVHD reactivity. Systemic release of the immune
brakes (checkpoints) may lead to induction and/or aggrava-
tion of GVHD in these patients. Recent studies on CTLA-4 and
PD-1 blockade in patients with relapsed acute myelog-
enous leukemia and Hodgkin lymphoma after allo-SCT
showed beneﬁcial GVT responses, but also raised concerns
about GVHD [47-56]. There are a few important caveats,
however. Interestingly, in the study by Haverkos et al. [56],
none of the patients treated with a haploidentical HLA-
mismatched transplant developed GVHD after anti-PD-1
treatment. All 4 patients received post-transplantation cy-
clophosphamide in addition to calcineurin inhibitor as GVHD
prevention. Thus, it is possible that incidence of GVHD after
checkpoint inhibitors administration may vary depending on
the type of GVHD prophylaxis. Further clinical studies are war-
ranted to establish guidelines for checkpoint interference after
allo-SCT. Alternatively, novel strategies for local interfer-
ence with checkpoint signaling pathways in the tumor
microenvironment, for instance, using targeted siRNA
nanoparticles, might hold the key to boost GVT immunity
without inducing and/or aggravating GVHD after allo-SCT.
In conclusion, we have shown that MiHA-speciﬁc CD8+ T
cells have a distinctive cosignalingmolecule expression proﬁle
comparedwith CMV-reactive CD8+ T cells. MiHA-speciﬁc CD8+
T cells highly express the inhibitory receptors PD-1, TIGIT, and
TIM-3, as well as the stimulatory receptors CD27 and CD28,
while having a recently activated early differentiation phe-
notype based on low KLRG-1 and CD57, accompanied by
CD137 positivity. Most importantly, high coexpression of PD-
1, TIGIT, and KLRG-1 on MiHA-reactive CD8+ T cells was
associated with relapse after allo-SCT. Taken together, these
data suggest that multiple cosignaling molecules may act to-
gether in regulating T cell-mediated tumor control. Treatment
with antibodies targeting different cosignaling molecules
would be an attractive adjuvant treatment strategy to boost
the potency of these highly activated, potentially dysfunc-
tional, tumor-reactive T cells to treat relapse after allo-SCT.
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